JP2017503833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503833A5 JP2017503833A5 JP2016548105A JP2016548105A JP2017503833A5 JP 2017503833 A5 JP2017503833 A5 JP 2017503833A5 JP 2016548105 A JP2016548105 A JP 2016548105A JP 2016548105 A JP2016548105 A JP 2016548105A JP 2017503833 A5 JP2017503833 A5 JP 2017503833A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- aryl
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims 30
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 25
- 125000001072 heteroaryl group Chemical group 0.000 claims 24
- 150000003573 thiols Chemical class 0.000 claims 23
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 22
- 125000003545 alkoxy group Chemical group 0.000 claims 21
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000002877 alkyl aryl group Chemical group 0.000 claims 15
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- -1 nitro, sulfonyl Chemical group 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 14
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical group [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 239000000651 prodrug Substances 0.000 claims 10
- 229940002612 prodrugs Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 8
- 125000004001 thioalkyl group Chemical group 0.000 claims 8
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000001408 amides Chemical group 0.000 claims 2
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- PDUSWJORWQPNRP-UHFFFAOYSA-N N-propan-2-ylacetamide Chemical compound CC(C)NC(C)=O PDUSWJORWQPNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- OEUAEFQARUZYLW-UHFFFAOYSA-N prop-1-en-2-olate Chemical group [CH2+]C([O-])=C OEUAEFQARUZYLW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461930757P | 2014-01-23 | 2014-01-23 | |
US61/930,757 | 2014-01-23 | ||
US201461977985P | 2014-04-10 | 2014-04-10 | |
US61/977,985 | 2014-04-10 | ||
PCT/US2015/012749 WO2015112898A1 (en) | 2014-01-23 | 2015-01-23 | Icariin derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020133800A Division JP2020189857A (ja) | 2014-01-23 | 2020-08-06 | イカリイン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017503833A JP2017503833A (ja) | 2017-02-02 |
JP2017503833A5 true JP2017503833A5 (US07846941-20101207-C00217.png) | 2018-02-08 |
Family
ID=53681995
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016548105A Pending JP2017503833A (ja) | 2014-01-23 | 2015-01-23 | イカリイン誘導体 |
JP2020133800A Pending JP2020189857A (ja) | 2014-01-23 | 2020-08-06 | イカリイン誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020133800A Pending JP2020189857A (ja) | 2014-01-23 | 2020-08-06 | イカリイン誘導体 |
Country Status (8)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009008099A (es) | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
JP6294476B2 (ja) | 2013-10-21 | 2018-03-14 | ▲魯▼南制▲薬▼集▲団▼股▲フン▼有限公司 | 血球減少を予防又は治療するための薬物の製造におけるアンヒドロイカリチンの使用 |
WO2016089950A1 (en) * | 2014-12-04 | 2016-06-09 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting intercellular adhesion molecule 4 (icam4) |
JP6903585B2 (ja) | 2015-03-13 | 2021-07-14 | レスバーロジックス コーポレイション | 補体関連疾患の治療のための組成物および治療方法 |
KR20180120746A (ko) * | 2016-03-11 | 2018-11-06 | 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 | 이카리인 및 이카리틴 유도체 |
CN107022526B (zh) * | 2017-03-16 | 2020-11-27 | 遵义医学院附属医院 | 一种诱导人羊膜间充质干细胞向神经元样细胞分化的方法 |
CN108484510B (zh) * | 2018-05-18 | 2020-05-05 | 东南大学 | 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用 |
KR102273061B1 (ko) * | 2019-06-05 | 2021-07-05 | 한국원자력연구원 | 향상된 항염 활성을 갖는 플라보노이드 화합물 및 이를 유효성분으로 포함하는 염증 개선용 조성물 |
GB202101728D0 (en) * | 2021-02-08 | 2021-03-24 | Floratek Pharma Ag | Compounds and their use treating cancer |
CN116947799B (zh) * | 2023-03-08 | 2024-05-03 | 上海泽德曼医药科技有限公司 | 酚类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
DE19501481A1 (de) * | 1995-01-19 | 1996-07-25 | Bayer Ag | 2,8-Disubstituierte Chinazolinone |
US6187779B1 (en) * | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
EP1133317A1 (de) | 1998-11-26 | 2001-09-19 | Pentapharm AG | Transportsystemkonjugate |
US6479499B1 (en) * | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
WO2002031109A2 (en) | 2000-10-13 | 2002-04-18 | University Of Lausanne | Intracellular delivery of biological effectors by novel transporter peptide sequences |
US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
US20050226943A1 (en) * | 2004-04-01 | 2005-10-13 | Xiaoqiang Yan | Extract of sophora flavescens flavonoids and uses thereof |
CN101429166B (zh) * | 2007-11-07 | 2013-08-21 | 上海特化医药科技有限公司 | 喹唑啉酮衍生物及其制备方法和用途 |
EP2262366A4 (en) * | 2008-04-18 | 2012-02-22 | Shenogen Pharma Group Ltd | COMPOUNDS AND METHODS FOR TREATING STROGEN RECEPTOR-RELATED DISEASES |
CN101843629B (zh) * | 2010-06-11 | 2012-03-14 | 首都医科大学宣武医院 | 淫羊藿苷和含有淫羊藿苷的淫羊藿黄酮的新用途 |
WO2012102937A2 (en) * | 2011-01-25 | 2012-08-02 | Irm Llc | Compounds that expand hematopoietic stem cells |
CA2840516A1 (en) * | 2011-06-29 | 2013-01-03 | President And Fellows Of Harvard College | Small molecule cd38 inhibitors and methods of using same |
US20130281398A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
-
2015
- 2015-01-23 WO PCT/US2015/012749 patent/WO2015112898A1/en active Application Filing
- 2015-01-23 MX MX2016009663A patent/MX2016009663A/es unknown
- 2015-01-23 EP EP15740729.7A patent/EP3097088A4/en not_active Ceased
- 2015-01-23 AU AU2015209143A patent/AU2015209143A1/en not_active Abandoned
- 2015-01-23 EP EP19205481.5A patent/EP3689420A1/en not_active Withdrawn
- 2015-01-23 BR BR112016016870A patent/BR112016016870A8/pt not_active IP Right Cessation
- 2015-01-23 CA CA2937905A patent/CA2937905A1/en not_active Abandoned
- 2015-01-23 JP JP2016548105A patent/JP2017503833A/ja active Pending
- 2015-01-23 US US15/113,500 patent/US20170044127A1/en not_active Abandoned
-
2019
- 2019-06-18 US US16/444,564 patent/US20200354331A1/en not_active Abandoned
- 2019-06-21 AU AU2019204363A patent/AU2019204363A1/en not_active Abandoned
-
2020
- 2020-08-06 JP JP2020133800A patent/JP2020189857A/ja active Pending